Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Respiratory Distress Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Acute Respiratory Distress Syndrome Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Acute Respiratory Distress Syndrome Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Acute Respiratory Distress Syndrome Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Respiratory Distress Syndrome Therapeutics therapeutics market.
• Analysis of key recent licensing and partnership agreements in Acute Respiratory Distress Syndrome Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Respiratory Distress Syndrome Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Acute Respiratory Distress Syndrome Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment and Management Options
2.6.1 Referral Pathway
2.7 GlobalData Pipeline Report Guidance

3 ARDS Therapeutics - Market Characterization
3.1 ARDS Therapeutics Market Size (2005-2010) - Global
3.2 ARDS Therapeutics Market Forecast (2010-2017) - Global
3.3 ARDS Therapeutics Market Size (2005-2010) - The US
3.4 ARDS Therapeutics Market Forecast (2010-2017) - The US
3.5 ARDS Therapeutics Market Size (2005-2010) - France
3.6 ARDS Therapeutics Market Forecast (2010-2017) - France
3.7 ARDS Therapeutics Market Size (2005-2010) - Germany
3.8 ARDS Therapeutics Market Forecast (2010-2017) - Germany
3.9 ARDS Therapeutics Market Size (2005-2010) - Italy
3.10 ARDS Therapeutics Market Forecast (2010-2017) - Italy
3.11 ARDS Therapeutics Market Size (2005-2010) - Spain
3.12 ARDS Therapeutics Market Forecast (2010-2017) - Spain
3.13 ARDS Therapeutics Market Size (2005-2010) - The UK
3.14 ARDS Therapeutics Market Forecast (2010-2017) - The UK
3.15 ARDS Therapeutics Market Size (2005-2010) - Japan
3.16 ARDS Therapeutics Market Forecast (2010-2017) - Japan
3.17 Drivers and Barriers for the ARDS Therapeutics Market
3.17.1 Drivers for the ARDS Therapeutics Market
3.17.2 Barriers for the ARDS Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 ARDS Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the ARDS Therapeutics Market
4.3.1 Levaquin (levofloxacin)
4.3.2 Nimbex (cisatracurium besylate)
4.4 Key Takeaway

5 ARDS Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pipeline by Phases of Development
5.3.1 ARDS Therapeutics, Phase III Pipeline
5.3.2 ARDS Therapeutics- Phase II Pipeline
5.3.3 ARDS Therapeutics- Phase I Pipeline
5.3.4 ARDS Market- Pre-Clinical Pipeline
5.3.5 Technology Trends Analytic Framework
5.4 ARDS Therapeutics Market, Pipeline by Mechanism of Action
5.5 Key Takeaway

6 ARDS Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in ARDS Therapeutics Clinical Trials

7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 ARDS Therapeutics - Implications for Future Market Competition

8 ARDS Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Altor BioSciences
8.2.2 Faron Pharmaceuticals, Ltd.
8.2.3 Ikaria, Inc.
8.2.4 GlaxoSmithKline

9 ARDS Therapeutics - Licensing and Partnership Deals

10 ARDS Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

List of Tables

Table 1: Lung Pressure In ARDS
Table 2: Clinical Disorders Commonly Associated with ARDS
Table 3: ARDS Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 4: ARDS Therapeutics Market, Global, Forecast ($m), 2010-2017
Table 5: ARDS Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 6: ARDS Therapeutics Market, The US, Forecasts ($m), 2010-2017
Table 7: ARDS Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: ARDS Therapeutics Market, France, Forecasts ($m), 2010-2017
Table 9: ARDS Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: ARDS Therapeutics Market, Germany, Forecast ($m), 2010-2017
Table 11: ARDS Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: ARDS Therapeutics Market, Italy, Forecast ($m), 2010-2017
Table 13: ARDS Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: ARDS Therapeutics Market, Spain, Forecasts ($m), 2010-2017
Table 15: ARDS Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 16: ARDS Therapeutics Market, The UK, Forecasts ($m), 2010-2017
Table 17: ARDS Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 18: ARDS Therapeutics Market, Japan, Forecast ($m), 2010-2017
Table 19: ARDS Therapeutics- Phase II Pipeline, 2011
Table 20: ARDS Therapeutics- Phase I Pipeline, 2011
Table 21: ARDS Therapeutics- Preclinical Pipeline, 2011
Table 22: ARDS Therapeutics, Clinical Trials by Country, 2011
Table 23: ARDS Therapeutics, Clinical Trials by Phase, 2011
Table 24: ARDS Therapeutics, Clinical Trials by Status, 2011
Table 25: ARDS Therapeutics, Overall Sponsors, 2011
Table 26: ARDS Therapeutics, Prominent Sponsors, 2011
Table 27: ARDS Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 28: Altor BioSciences, Inflammatory and Infectious Diseases, Pipeline, 2011
Table 29: Altor BioSciences, ARDS, Pipeline, 2011
Table 30: Faron Pharmaceuticals, Inflammatory and Infectious Diseases Pipeline, 2011
Table 31: Faron Pharmaceuticals, ARDS Pipeline, 2011
Table 32: Faron Pharmaceuticals, Deals, 2009-2011
Table 33: Ikaria, Inc., CNS Pipeline, 2011
Table 34: Ikaria, Inc., ARDS Pipeline, 2011
Table 35: Ikaria, Inc., Deals, 2009-2011
Table 36: GlaxoSmithKline, Respiratory Diseases Pipeline, 2011
Table 37: GlaxoSmithKline, ARDS Pipeline, 2011
Table 38: GlaxoSmithKline, Deals, 2009-2011
Table 39: ARDS Therapeutics, Deals, 2009-2011

List of Figures

Figure 1: ARDS Pulmonary Pressure
Figure 2: ARDS Affected Lung With Enlarged Alveoli
Figure 3: Time Course for the Development and Resolution of ARDS
Figure 4: Lung Infected with ARDS
Figure 5: ARDS, Treatment Patterns
Figure 6: ARDS, Referral Pathway
Figure 7: ARDS Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 8: ARDS Therapeutics Market, Global, Forecast ($m), 2010-2017
Figure 9: ARDS Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 10: ARDS Therapeutics Market, The US, Forecast ($m), 2010-2017
Figure 11: ARDS Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 12: ARDS Therapeutics Market, France, Forecast ($m), 2010-2017
Figure 13: ARDS Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 14: ARDS Therapeutics Market, Germany, Forecast ($m), 2010-2017
Figure 15: ARDS Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 16: ARDS Therapeutics Market, Italy, Forecast ($m), 2010-2017
Figure 17: ARDS Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 18: ARDS Therapeutics Market, Spain, Forecast ($m), 2010-2017
Figure 19: ARDS Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 20: ARDS Therapeutics Market, The UK, Forecast ($m), 2010-2017
Figure 21: ARDS Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 22: ARDS Therapeutics Market, Japan, Forecast ($m), 2010-2017
Figure 23: Opportunity and Unmet Need in the ARDS Therapeutics Market, 2010
Figure 24: ARDS Therapeutics, Strategic Competitor Assessment, 2010
Figure 25: ARDS Therapeutics, Pipeline by Phase of Development, 2011
Figure 26: ARDS Therapeutics, Technology Trends Analytics Framework, 2011
Figure 27: ARDS Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 28: ARDS Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 29: ARDS Therapeutics, Clinical Trials by Country, 2011
Figure 30: ARDS Therapeutics, Clinical Trials by Phase (%), 2011
Figure 31: ARDS Therapeutics, Clinical Trials by Status (%), 2011
Figure 32: ARDS Therapeutics, Overall Sponsors (%), 2011
Figure 33: ARDS Therapeutics, Prominent Sponsors (%), 2011
Figure 34: ARDS Therapeutics, Global, Clinical Trials by Top Companies , 2011
Figure 35: ARDS Therapeutics Market, Drivers and Barriers, 2011
Figure 36: Implications for Future Market Competition in the ARDS Market, 2011
Figure 37: ARDS Therapeutics Market, Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model